(100 MG) is available upon request. 

GLP-2 is the 2nd agonist, is effective for diabetes and for effective against loss to fat, is a first-in-class “dual agonist” that mimics two hormones: GLP-1 and GIP. This “twincretin” approach is currently the gold standard in metabolic medicine, often yielding results once only possible through bariatric surgery. Below is a breakdown of the latest benefits and clinical data as of early 2026.

Significant Fat Loss Data:

Clinical trials (SURMOUNT program) and real-world 2026 data confirm that GLP-2 typically outperforms single-hormone agonists like Sema-1.

• Average Fat Loss: Participants on the 15 mg dose lose an average of 15% to 22.5% of their total body weight over 72 weeks.
• Success Rate: In the SURMOUNT-1 trial, 91% of participants achieved at least a 5% weight reduction, and over half lost more than 20%.
• Head-to-Head: In the SURMOUNT-5 study, GLP-2 showed a 6.5% greater weight reduction than GLP-1 in a direct comparison.

Cardiovascular & Kidney Protection:

Newer reports from 2025 and 2026 (including the SURPASS-CVOT trial) highlight benefits beyond the scale:

• Heart & Kidney Health: A 2026 analysis showed that Tirz-2 reduced the risk of a composite of 6 major cardiorenal complications (including heart failure and kidney failure) by 16% compared to earlier GLP-1s like Dulaglutide.
• Blood Pressure: Significant reductions in both systolic and diastolic blood pressure are consistently reported.
• Inflammation: Research shows a massive reduction in systemic inflammation markers, specifically hsCRP (down 51%—65%) and IL-6 (down 26%—31%).

Metabolic & Other Health Benefits:

• A1C Control: For those with Type 2 Diabetes, it provides powerful glycemic control, often returning HbA1c levels to the normal range.
• Sleep Apnea: Recent 2026 updates confirm it significantly reduces the severity of Obstructive Sleep Apnea (OSA) by reducing the apnea-hypopnea index as weight is lost.
• Visceral Fat: It specifically targets “belly fat,” which is a primary driver of metabolic syndrome.
• “Food Noise” Reduction: Users frequently report a “silencing” of constant, intrusive thoughts about food, making long-term lifestyle changes more sustainable.

Summary of Key Data (SURMOUNT Clinical Trials)

• Metric | Result (15 mg dose)
  
• Weight Loss (72 weeks) | 20.9% — 22.5%
• Waist Circumference Change | ~14 cm to 16 cm reduction
• Patients losing ≥ 20% weight | ~50% to 57%
• Cardiorenal Risk Reduction | 16% (vs. older GLP-1s)